Prevention of NSAID-related ulcers

Comprehensive Therapy

Volumn 26, Issue 2, 2000, Pages 103-108

  Lanza, F L ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; KETOROLAC; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OXAPROZIN; PIROXICAM; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; SUCRALFATE;

ARTICLE; DRUG EFFICACY; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER PYLORI; HUMAN; PATIENT SELECTION; PROPHYLAXIS; RISK ASSESSMENT; ULCER;

EID: 0033861599     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12019-000-0019-4     Document Type: Article

References (35)

1. Effects of nonsteroidal anti-inflammatory drugs on endogenous gastrointestinal prostaglandins and therapeutic strategies for prevention and treatment of nonsteroidal, anti-inflammatory drug-induced damage
2. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use
3. Upper gastrointestinal lesions in elderly patients presenting for endoscopy: Relevance of NSAID usage
4. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomized, double-blind, placebo-controlled trial
5. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: A meta-analysis
6. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforation and hemorrhage
7. Nonsteroidal anti-inflammatory drugs and peptic ulcer perforation
8. Corticosteroid use in peptic ulcer disease; Role of nonsteroidal anti-inflammatory drugs
9. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease
10. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs
11. Risks of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs
12. Variability in the risk of major gastrointestinal complications from nonaspirin anti-inflammatory drugs
13. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other hypertensive drugs
14. Prevention of gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs: Controlled trial of ranitidine
15. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs
16. Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs
17. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs
18. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer in randomized control trial
19. Sucralfate
20. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous nonsteroidal anti-inflammatory drug therapy
21. Omeprazole for ulcers associated with nonsteroidal anti-inflammatory drugs
22. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs
23. Prevention of NSAID-induced gastric ulcer with misoprostol: Multicentre, double-blind placebo-controlled trial
24. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs
25. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: A comparison of three regimens
26. Efficacy of 12 months misoprostol as prophylaxis against NSAID-induced gastric ulcers: A placebo-controlled trial
27. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: A prospective, double-blind, multicenter study
28. Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease
29. Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury
30. Nonsteroidal anti-inflammatory drug-associated gastric ulcers do not require Helicobacter pylori for their development
31. Helicobacter pylori: A risk of severity factor of nonsteroidal anti-inflammatory drug-induced gastropathy
32. Helicobacter pylori infection and development of duodenal ulcer in arthritic patients receiving chronic NSAID therapy: The Misoprostol Study Group
33. Randomised trial of eradication of Helicobacter pylori before nonsteroidal anti-inflammatory drug therapy to prevent peptic ulcers
34. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor
35. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than aspirin or ibuprofen